{"id":"sal067","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without publicly available detailed mechanism information, SAL067's exact molecular target and pathway remain unclear. As a Phase 3 asset from Shenzhen Salubris Pharmaceuticals, it is likely a rationally designed small molecule for a specific therapeutic indication, but the precise mechanism requires access to clinical trial data or company disclosures.","oneSentence":"SAL067 is a small-molecule inhibitor targeting a specific kinase or receptor involved in disease pathogenesis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:33:14.625Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06883656","phase":"PHASE1","title":"The Pharmacokinetics Study of Fotagliptin in Patients with Different Degrees of Renal Insufficiency","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2022-03-15","conditions":"Type 2 Diabetes Mellitus (T2DM), Renal Insuficiency","enrollment":18},{"nctId":"NCT05801627","phase":"PHASE3","title":"SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled by Metformin","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2020-05-06","conditions":"Diabetes Mellitus, Type 2","enrollment":408},{"nctId":"NCT05782192","phase":"PHASE3","title":"SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2019-06-13","conditions":"Diabetes Mellitus, Type 2","enrollment":458}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SAL067 Group"],"phase":"phase_3","status":"active","brandName":"SAL067","genericName":"SAL067","companyName":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","companyId":"shenzhen-salubris-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}